Cardiology

A new study found cardiovascular risks can last ≥ 3 years after PM2.5 exposure.

Deepak Bhatt, MD, MPH, looks ahead to discuss what he is most excited about from the upcoming late-breaking clinical trials sessions at the American College of Cardiology 2024 annual meeting

An expert in cardiology shares clinical trial findings of emerging and approved cardiac myosin inhibitors for the treatment of oHCM.

Dr James L. Januzzi reviews the use of cardiac myosin inhibitors for the management of oHCM.

This American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.

An expert cardiologist examines unmet needs and bridging the gap in care for patients with oHCM.

James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.

Ahmad Masri, MD, MS, provides an update on the the development of the cardiac myosin inhibitor class and offers perspective on what the future might hold for the class beyond cardiomyopathy.

Tom Nguyen, MD, discusses a recent study he led comparing outcomes of TAVR explantation based on transcatheter heart valve type.

Older adults who use a salt substitute had a 40% lower incidence of experiencing hypertension than people who use regular salt.

FDA advisory committee votes 13-1 that the benefits outweigh the risk of use for Abbott's TriClip for tricuspid regurgitation, pending FDA decision expected in 2024.

Michelle Kittleson, MD, PhD, provides insight into the potential impact of a new risk score for heart transplant allocation as well as the need for more equitable cardiovascular care in the US.

A novel risk score developed by University of Chicago investigators outperformed conventional models in predicting death in heart transplant candidates, which could help bring the field closer to optimal and equitable allocation.

A recent survey indicates many US adults are unaware of their vital health metrics, highlighting the need for increased education on heart disease prevention.

Anticoagulation and antiplatelet therapy show no significant difference in recurrent stroke risk among patients with cryptogenic stroke and evidence of atrial cardiopathy.

Deepak Bhatt, MD, MPH, discusses the need to improve in-hospital initiation and uptitration of guideline-directed medical therapy in heart failure.

A new study found balance and falling were linked to an increased risk of all-cause mortality, as well as cause-specific mortality from cardiovascular disease and diabetes.

Blood thinners added to clot-busting medication did not improve 90-day stroke outcomes, leading to early discontinuation of the MOST trial.

This recap of top cardiology news from January 2024 spotlights pipeline updates, new guidance on peripheral interventions, and a celebration of what may be the single most impactful public health address in the history of the United States.

Findings highlight the potential benefits of implementing home-based screening for albuminuria in the general population to reduce the burden of kidney and cardiovascular diseases while maintaining cost-effectiveness.

The FDA's acceptance of the NDA for acoramidis in ATTR-CM was announced on February 05, 2024 and assigns a November 2024 PDUFA for the agent.

Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.

Tirzepatide, a dual GLP-1/GIP agonist approved for diabetes and obesity, was associated with significant blood pressure reductions in an analysis of the SURMOUNT-1 trial.

Although a new study found antidepressants from SSRI or SNRI did not increase the risk of hemorrhagic stroke or other serious bleeding in ischemic stroke survivors, the risk increased when taking antidepressants of other classes and anti-platelet medications.

The FDA approval of Edwards Lifesciences EVOQUE tricuspid valve replacement system for treatment of symptomatic severe tricuspid regurgitation is the first of its kind for a transcatheter therapy.